Understand the source comparison
Peptides for Crohn's Disease Research Compared: Mechanism Comparison
The table below compares the three most studied peptides for Crohn's disease research based on primary mechanism, optimal research application, typical dosing ranges in animal models, and key outcome measures that demonstrate mechanism-specific effects. BPC-15
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the three most studied peptides for Crohn's disease research based on primary mechanism, optimal research application, typical dosing ranges in animal models, and key outcome measures that demonstrate mechanism-specific effects.
- BPC-157
- Angiogenesis promotion via VEGF/FGF-2 upregulation; accelerates mucosal healing
- Acute injury models; ulcerative phase replication; tissue repair velocity studies
- 10–50 μg/kg IP or oral daily
- Ulcer area reduction, vessel density at wound margins, collagen deposition, histological damage scores
- Best for acute mucosal damage models where tissue regeneration is the primary endpoint. Less effective in chronic immune-driven inflammation
- Thymosin Beta-4 (Tβ4)
- G-actin sequestration; immune cell migration inhibition; TNF-α/IL-6 downregulation via NF-κB interference
- Chronic inflammation models; immune cell behaviour studies; cytokine profiling experiments
- 1–6 mg/kg IP twice weekly
- Neutrophil/macrophage infiltration density, TNF-α/IL-6 serum levels, mucosal damage scores, flow cytometry immune profiles
- Ideal for models investigating immune dysregulation mechanisms. Requires baseline cytokine profiling to demonstrate effect
- KPV
- Melanocortin receptor (MC1R) agonism; NF-κB nuclear translocation blockade
- Transcriptional inflammation studies; oral administration models; MC1R-specific pathway research
- 5–25 mg/kg oral daily
- NF-κB nuclear translocation assays, IL-1β/IL-6 mRNA expression, colonic MPO activity, epithelial barrier integrity
- Most specific mechanism but narrow application. Requires MC1R expression confirmation in target tissue; effect abolished in MC1R knockout models